Sanofi chooses Meeker to head Genzyme unit; FDA approves Lundbeck seizure drug Onfi;

> Six months into its integration of Genzyme, Sanofi ($SNY) tapped Genzyme's COO, David Meeker, to take the helm there. He will report to Sanofi chief Christopher Viehbacher. Item

> Lundbeck got the FDA nod for Onfi, its therapy for a severe form of epilepsy known as Lennox-Gastaut Syndrome. News

> Strong growth in the U.S. helped India's Dr. Reddy's Laboratories make up for slow sales in its domestic market and post forecast-beating profits for its fiscal second quarter. Report

> A Chinese manufacturer of veterinary medicines sued Pfizer's ($PFE) animal health division after the U.S.-based company stopped selling its 3-Nitro product for safety reasons. Article

> Companies' disregard of the Association of the British Pharmaceutical Industry's communications code is a growing problem, a U.K. compliance expert said. Story

And Finally... Human papillomavirus, already linked to several types of cancer, may also increase the risk of heart disease, a new study suggests. News

Suggested Articles

Johnson & Johnson and Bayer’s Xarelto is working to reverse a sales slide, and a new indication could help.

AZ's FluMist will be dramatically limited in the U.S. this flu season because of production problems, a spokeswoman said.

To get its $12 billion opioid deal off the ground, Purdue Pharma pushed for a stay on thousands of lawsuits against it. Last week, a judge signed off.